During the past decade, Semmelweis University Faculty of Medicine conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 7 clinical trials were completed, i.e. on average, 70% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Semmelweis University Faculty of Medicine" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Crinetics Pharmaceuticals Inc." with 2 trials sponsored, "Ionis Pharmaceuticals, Inc." with 2 trials sponsored, "Semmelweis University" with 2 trials sponsored and "Shire" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Semmelweis University Faculty of Medicine" #1 collaborator was "Eurofins Optimed" with 1 trials as a collaborator, "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator, "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator, "Institute of Cancer Research, United Kingdom" with 1 trials as a collaborator and "Pharma Patent Kft." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Semmelweis University Faculty of Medicine" are "Acromegaly" (3 trials), "Hypoparathyroidism" (2 trials), "Non-Hodgkin's Lymphoma" (2 trials), "Castrate-Resistant Prostate Cancer" (1 trials) and "Chronic Lymphocytic Leukemia" (1 trials). Many other conditions were trialed in "Semmelweis University Faculty of Medicine" in a lesser frequency.

Most popular intervention types in "Semmelweis University Faculty of Medicine" are "Drug" (17 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (4 trials), "Obinutuzumab" (3 trials), "Placebo" (3 trials), "Prednisone" (3 trials) and "Bendamustine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Semmelweis University Faculty of Medicine" are 18 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Semmelweis University Faculty of Medicine". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Semmelweis University Faculty of Medicine, 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Semmelweis University Faculty of Medicine, 5 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".